Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
CAPTIVATE Phase 3 interim analysis for claseprubart showed a 75% response rate among the first 40 participants in Part A, exceeding the 50% bar, with no serious infections, drug-induced lupus symptoms, serious adverse events, or safety discontinuations.
Sep 5, 2026 ·
Yahoo Finance
















